Evidence map›Paper›PMID 38027201›Full record

ArticleFrontiers in endocrinology2023

Exploring the potential mechanisms of Tongmai Jiangtang capsules in treating diabetic nephropathy through multi-dimensional data.

Yi Liu, Xin Cui, Xuming Zhang, Zhuoting Xie, Weili Wang, Junyu Xi, Yanming Xie

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yi Liu *Institute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences, Beijing, China.
Xin Cui *Institute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences, Beijing, China.
Xuming Zhang *Institute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences, Beijing, China.
Zhuoting Xie *Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin, China.
Weili WangInstitute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences, Beijing, China.
Junyu XiInstitute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences, Beijing, China.
Yanming XieInstitute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences, Beijing, China.
China Academy of Chinese Medical Sciences · CNSecond Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic nephropathy (DN) is a prevalent and debilitating disease that represents the leading cause of chronic kidney disease which imposes public health challenges Tongmai Jiangtang capsule (TMJT) is commonly used for the treatment of DN, albeit its underlying mechanisms of action are still elusive. Methods: This study retrieved databases to identify the components and collect the targets of TMJT and DN. Target networks were constructed to screen the core components and targets. Samples from the GEO database were utilized to perform analyses of targets and immune cells and obtain significantly differentially expressed core genes (SDECGs). We also selected a machine learning model to screen the feature genes and construct a nomogram. Furthermore, molecular docking, another GEO dataset, and Mendelian randomization (MR) were utilized for preliminary validation. We subsequently clustered the samples based on SDECG expression and consensus clustering and performed analyses between the clusters. Finally, we scored the SDECG score and analyzed the differences between clusters. Results: This study identified 13 SDECGs between DN and normal groups which positively regulated immune cells. We also identified five feature genes ( Conclusion: TMJT may alleviate DN via core components (e.g. Denudatin B, hancinol, hirudinoidine A) targeting SDECGs (e.g. SRC, EGF, GAPDH), with the involvement of feature genes and modulation of immune and inflammation-related pathways. These findings have potential implications for clinical practice and future investigations.

Indexed as

Diabetes MellitusDiabetic NephropathiesCluster AnalysisDatabases, FactualEpidermal Growth FactorHumansMolecular Docking SimulationEpidermal Growth Factorbioinformaticsmachine learningMendelian randomization (MR)molecular dockingnetwork pharmacologynomogramTongmai Jiangtang capsule (TMJT)Traditional Chinese Medicine

Identifiers

PMID38027201
PMCPMC10654657
OpenAlexW4388126753

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.